Since COX-2 is overexpressed in many lung cancers and COX-2/PGE2 signaling has been implicated in cancer progression, it is considered that use of COX-2 inhibitors is beneficial as lung cancer therapy. The gene discussed is PTGS2; the disease is lung cancer.